AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30884045 — intervention group
Group type: COMPARATOR
Intervention: Artificial saliva (control)
Number of subjects: 32
Study 30449440 — intervention group
Group type: EXPERIMENTAL
Intervention: Wristband acupressure at P6 Neiguan point applied during the first 12 hours after operation
Number of subjects: 97
Study 30449440 — intervention group
Group type: COMPARATOR
Intervention: Antiemetics during and after operation
Number of subjects: 97
Study 28215665 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of trastuzumab (8 mg/kg IV once, then 6 mg/kg every 3 weeks)
Number of subjects: 5099
Study 28215665 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of trastuzumab (8 mg/kg IV once, then 6 mg/kg every 3 weeks)
Number of subjects: 5099
Study 28215665 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 5099
Study 28215665 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of trastuzumab
Number of subjects: 5099
Study 28215665 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of trastuzumab
Number of subjects: 5099
Study 26284747 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Glasses
Number of subjects: 3001
Study 26284747 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher for Free Glasses
Number of subjects: 3001
Study 26284747 — intervention group
Group type: COMPARATOR
Intervention: Control (Glasses Prescriptions Only)
Number of subjects: 3001
Study 23401923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Ventilation (IPPV)
Number of subjects: 60
Study 23401923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Controlled Ventilation (PCV)
Number of subjects: 60
Study 21651803 — intervention group
Group type: EXPERIMENTAL
Intervention: EARS II (HP® iPAQ)
Number of subjects: 12
Study 21651803 — intervention group
Group type: COMPARATOR
Intervention: Pen and Paper (P&P)
Number of subjects: 12
Study 18513526 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (CCR)
Number of subjects: 770
Study 18513526 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 770
Study 16580575 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release metoprolol succinate (25, 100, or 400 mg)
Number of subjects: 1092
Study 16580575 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release felodipine (2.5, 10, or 20 mg)
Number of subjects: 1092
Study 16580575 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of extended-release metoprolol succinate and extended-release felodipine (various combinations)
Number of subjects: 1092
Study 16580575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1092
Study 16580575 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combination (ER metoprolol succinate 25 mg/ER felodipine 2.5 mg)
Number of subjects: 1092
Study 12664053 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface modifying additives (SMA)
Number of subjects: 76
Study 12664053 — intervention group
Group type: COMPARATOR
Intervention: Untreated circuits (Control)
Number of subjects: 76
Study 10669338 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV human hyperimmune immunoglobulin (HIVIG) 200 mg/kg
Number of subjects: 30
Study 10669338 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV human hyperimmune immunoglobulin (HIVIG) 400 mg/kg
Number of subjects: 30
Study 10669338 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV human hyperimmune immunoglobulin (HIVIG) 800 mg/kg
Number of subjects: 30
Study 10669338 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 9336105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pack A
Number of subjects: 10
Study 9336105 — intervention group
Group type: COMPARATOR
Intervention: Pack B
Number of subjects: 10
Study 8403783 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (0, 1, 2, 5, or 10 ng min-1 kg-1)
Number of subjects: 7
Study 3542271 — intervention group
Group type: EXPERIMENTAL
Intervention: JM8
Number of subjects: 16
Study 3542271 — intervention group
Group type: EXPERIMENTAL
Intervention: JM9
Number of subjects: 16
Study 31764842 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS) TKA
Number of subjects: 60
Study 31764842 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 60
Study 29990671 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted decision aids (DAs)
Number of subjects: 0
Study 29990671 — intervention group
Group type: COMPARATOR
Intervention: Generic decision aids (DAs)
Number of subjects: 0
Study 27887610 — intervention group
Group type: COMPARATOR
Intervention: m-health group using BENECA app for 2 months with usual care information
Number of subjects: 0
Study 27887610 — intervention group
Group type: EXPERIMENTAL
Intervention: integral group using BENECA app and face-to-face rehabilitation for 8 weeks
Number of subjects: 0
Study 27887610 — intervention group
Group type: EXPERIMENTAL
Intervention: integral group
Number of subjects: 0
Study 27887610 — intervention group
Group type: COMPARATOR
Intervention: m-health group
Number of subjects: 0
Study 1593359 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (1 mg/kg per dose) intravenously every 24 hours for five doses
Number of subjects: 22
Study 1593359 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg per dose) with metolazone (0.2 mg/kg per dose) enterally with doses 3 and 4 of furosemide
Number of subjects: 22
Study 1593359 — intervention group
Group type: COMPARATOR
Intervention: Metolazone (0.2 mg/kg per dose) enterally every 24 hours for five doses
Number of subjects: 22
Study 22450530 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ml of oral 12.5% carbohydrate solution
Number of subjects: 60
Study 22450530 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (flavoured water)
Number of subjects: 60
Study 20408061 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 104
Study 20408061 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 104
Study 20408061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ACT and CBT
Number of subjects: 104
Study 18690345 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (2 mg) + trimegestone (0.5 mg)
Number of subjects: 186
Study 18690345 — intervention group
Group type: COMPARATOR
Intervention: Estradiol (2 mg) + dydrogesterone (10 mg)
Number of subjects: 186
Study 15720047 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-urban villages
Number of subjects: 1013
Study 15720047 — intervention group
Group type: COMPARATOR
Intervention: Rural villages
Number of subjects: 1013
Study 15720047 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt consumption
Number of subjects: 1013
Study 15720047 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt added at the table
Number of subjects: 1013
Study 12875749 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein ablation
Number of subjects: 1171
Study 12875749 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic medications
Number of subjects: 1171
Study 10476903 — intervention group
Group type: EXPERIMENTAL
Intervention: No barrier membrane (Group A)
Number of subjects: 29
Study 10476903 — intervention group
Group type: COMPARATOR
Intervention: Occlusive resorbable collagen membrane (Group B)
Number of subjects: 29
Study 8961473 — intervention group
Group type: EXPERIMENTAL
Intervention: Monomicrobial SBE
Number of subjects: 134
Study 8961473 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymicrobial SBE
Number of subjects: 134
Study 8961473 — intervention group
Group type: COMPARATOR
Intervention: Quinolones prophylaxis
Number of subjects: 134
Study 2646332 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC-detergent foam
Number of subjects: 14
Study 2646332 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoride toothpaste
Number of subjects: 14
Study 1111446 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcal clumping test
Number of subjects: 0
Study 1111446 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic heparin or aspirin
Number of subjects: 0
Study 30795734 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs selected based on FST scores
Number of subjects: 2
Study 30795734 — intervention group
Group type: COMPARATOR
Intervention: Randomly selected 20 K SNP subsets
Number of subjects: 2
Study 30795734 — intervention group
Group type: COMPARATOR
Intervention: All 400 K SNPs
Number of subjects: 2
Study 30795734 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 K SNPs selected based on FST scores
Number of subjects: 2
Study 30795734 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 K SNPs selected based on FST scores
Number of subjects: 2
Study 30795734 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 K SNPs selected based on FST scores
Number of subjects: 2
Study 28859646 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a decision aid (DA)
Number of subjects: 128
Study 28859646 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 128
Study 25403844 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP group
Number of subjects: 111
Study 25403844 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 111
Study 25403844 — intervention group
Group type: EXPERIMENTAL
Intervention: Acting out defensive style and BDI
Number of subjects: 111
Study 22330131 — intervention group
Group type: EXPERIMENTAL
Intervention: HCl infusion (0.15 M for 30 minutes)
Number of subjects: 21
Study 22330131 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 21
Study 21487259 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg orally)
Number of subjects: 14
Study 21487259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18827611 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral plus written information
Number of subjects: 102
Study 18827611 — intervention group
Group type: COMPARATOR
Intervention: Oral information only
Number of subjects: 102
Study 21182550 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping episodes
Number of subjects: 372
Study 15927054 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy‐‐General
Number of subjects: 1277
Study 15927054 — intervention group
Group type: EXPERIMENTAL
Intervention: European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire
Number of subjects: 1277
Study 15927054 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Living Index‐‐Cancer
Number of subjects: 1277
Study 12455679 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal lobe damage (patients with unilateral frontal lobe lesions)
Number of subjects: 3
Study 12455679 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control subjects
Number of subjects: 3
Study 12455679 — intervention group
Group type: COMPARATOR
Intervention: Young control subjects
Number of subjects: 3
Study 9538308 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg once daily)
Number of subjects: 50
Study 9538308 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol CR (100 mg once daily)
Number of subjects: 50
Study 8273968 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-99m-sestamibi localization
Number of subjects: 42
Study 8273968 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative radionuclide scanning)
Number of subjects: 42
Study 2658454 — intervention group
Group type: COMPARATOR
Intervention: Sandostatin (100 micrograms)
Number of subjects: 10
Study 66331 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 30
Study 66331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29239259 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol
Number of subjects: 120
Study 29239259 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen
Number of subjects: 120
Study 27605629 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 388626 (200 mg)
Number of subjects: 0
Study 27605629 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 388626 (100 mg)
Number of subjects: 0
Study 27605629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27605629 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS 388626
Number of subjects: 0
Study 23892729 — intervention group
Group type: COMPARATOR
Intervention: Standard swallowing exercises (N = 14)
Number of subjects: 29
Study 23892729 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraBite® Jaw Motion Rehabilitation System™ swallowing exercises (N = 15)
Number of subjects: 29
Study 21239075 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose clopidogrel (150 mg/day for 1 month)
Number of subjects: 192
Study 21239075 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose clopidogrel (75 mg/day for 1 month)
Number of subjects: 192
Study 21239075 — intervention group
Group type: COMPARATOR
Intervention: Control group (75 mg/day for 1 month)
Number of subjects: 192
Study 21239075 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 192
Study 20148806 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen nasal challenge
Number of subjects: 22
Study 20148806 — intervention group
Group type: COMPARATOR
Intervention: CCR4 antagonist
Number of subjects: 22
Study 18719447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sciatic (single‐shot) and continuous femoral block (48 h)
Number of subjects: 0
Study 18719447 — intervention group
Group type: COMPARATOR
Intervention: Morphine patient‐controlled analgesia
Number of subjects: 0
Study 16115358 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA-enriched dairy products (1.43 g c9,t11 CLA/d; 4.71 g tVA/d)
Number of subjects: 0
Study 16115358 — intervention group
Group type: COMPARATOR
Intervention: Control dairy products (0.17 g c9,t11 CLA/d; 0.31 g tVA/d)
Number of subjects: 0
Study 12464460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 0
Study 12464460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10051075 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position with inhaled nitric oxide (10 ppm)
Number of subjects: 14
Study 10051075 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of nitric oxide (10 ppm) in supine position
Number of subjects: 14
Study 10051075 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of prone position and inhaled nitric oxide
Number of subjects: 14
Study 7549052 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 121
Study 7549052 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 121
Study 2268124 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 202
Study 2268124 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI imaging
Number of subjects: 202
Study 2268124 — intervention group
Group type: EXPERIMENTAL
Intervention: CT and MRI combined
Number of subjects: 202
Study 285821 — intervention group
Group type: EXPERIMENTAL
Intervention: Stab wounds over the roots of the incisors
Number of subjects: 31
Study 285821 — intervention group
Group type: COMPARATOR
Intervention: Papillar wounds inflicted at the same level
Number of subjects: 31
Study 31807849 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) with paclitaxel
Number of subjects: 137
Study 31807849 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA) ± bare metal stenting (BMS)
Number of subjects: 137
Study 30721635 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 52
Study 30721635 — intervention group
Group type: COMPARATOR
Intervention: Copper intrauterine device (IUD)
Number of subjects: 52
Study 29084657 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 160
Study 29084657 — intervention group
Group type: COMPARATOR
Intervention: Pefloxacin
Number of subjects: 160
Study 26530931 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA, 40 min)
Number of subjects: 9
Study 26530931 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS (2 mA, 40 min)
Number of subjects: 9
Study 26530931 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 9
Study 23462319 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese individuals with binge eating disorder (BED)
Number of subjects: 57
Study 23462319 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-BED obese individuals (OB)
Number of subjects: 57
Study 23462319 — intervention group
Group type: COMPARATOR
Intervention: Lean control subjects (LC)
Number of subjects: 57
Study 21251129 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (positive control drug)
Number of subjects: 7
Study 21251129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 21251129 — intervention group
Group type: COMPARATOR
Intervention: Placebo-baseline-adjusted QTc prolongation
Number of subjects: 7
Study 21251129 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-QT vs FDA-approved measurements
Number of subjects: 7
Study 21251129 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-induced QTc prolongation adjusted for placebo
Number of subjects: 7
Study 18534397 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted total knee arthroplasty (CAS)
Number of subjects: 115
Study 18534397 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty (CONV)
Number of subjects: 115
Study 18534397 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with coronal alignment within 3 degrees of neutral
Number of subjects: 115
Study 17868736 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic live donor nephrectomy
Number of subjects: 69
Study 17868736 — intervention group
Group type: COMPARATOR
Intervention: Open live donor nephrectomy
Number of subjects: 69
Study 12898456 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine (1.5 mg. kg(‐1). min(‐1))
Number of subjects: 11
Study 12898456 — intervention group
Group type: COMPARATOR
Intervention: Control (unlabeled glucose at 22 micromol. kg(‐1). min(‐1))
Number of subjects: 11
Study 10889425 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation silicone lens
Number of subjects: 128
Study 10889425 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-piece acrylic lens
Number of subjects: 128
Study 10889425 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-piece second-generation silicone lens
Number of subjects: 128
Study 10889425 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of lens designs
Number of subjects: 128
Study 8744911 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria proposed by patients
Number of subjects: 344
Study 8744911 — intervention group
Group type: COMPARATOR
Intervention: Criteria proposed by dentists
Number of subjects: 344
Study 8744911 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient criteria
Number of subjects: 344
Study 8744911 — intervention group
Group type: COMPARATOR
Intervention: Dentist criteria
Number of subjects: 344
Study 1417015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 42
Study 1417015 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 42
Study 3904885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (2000 mg/day, range 800-3200)
Number of subjects: 20
Study 3904885 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (12 mg/day, range 6-24)
Number of subjects: 20
Study 3904885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 20
Study 3904885 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 20
Study 3904885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride and Haloperidol
Number of subjects: 20
Study 30797750 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment for patients with thyroid-stimulating hormone values of more than 10 mIU/L
Number of subjects: 0
Study 30797750 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of therapy for abnormal thyroid function
Number of subjects: 0
Study 30003561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (PC)
Number of subjects: 131
Study 30003561 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 131
Study 26882833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg of 5% ketamine)
Number of subjects: 33
Study 26882833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg of 2% lidocaine)
Number of subjects: 33
Study 26882833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 33
Study 26882833 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33
Study 25423698 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conserving surgery (BCS)
Number of subjects: 61
Study 25423698 — intervention group
Group type: COMPARATOR
Intervention: Total mastectomy (TM)
Number of subjects: 61
Study 23093664 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.3 units · kg(‐1))
Number of subjects: 12
Study 23093664 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.6 units · kg(‐1))
Number of subjects: 12
Study 23093664 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (1.2 units · kg(‐1))
Number of subjects: 12
Study 23093664 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 12
Study 23093664 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite M2
Number of subjects: 12
Study 19969374 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus atomoxetine (40‐120 mg/d)
Number of subjects: 261
Study 19969374 — intervention group
Group type: COMPARATOR
Intervention: Sertraline plus placebo
Number of subjects: 261
Study 19969374 — intervention group
Group type: COMPARATOR
Intervention: Sertraline monotherapy
Number of subjects: 261
Study 17850609 — intervention group
Group type: EXPERIMENTAL
Intervention: simplified papilla preservation
Number of subjects: 10
Study 17850609 — intervention group
Group type: COMPARATOR
Intervention: modified Widman flap
Number of subjects: 10